Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β(2)-agonists in obstructive lung diseases: a population-based, observational st...

por Björnsdóttir, U S, Sigurðardóttir, S T, Jonsson, J S, Jonsson, M, Telg, G, Thuresson, M, Naya, I, Gizurarson, S
Publicado 2014

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations

por Kuna, P, Peters, M J, Manjra, A I, Jorup, C, Naya, I P, Martínez-Jimenez, N E, Buhl, R
Publicado 2007

Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial

por Maltais, F., Naya, I. P., Vogelmeier, C. F., Boucot, I. H., Jones, P. W., Bjermer, L., Tombs, L., Compton, C., Lipson, D. A., Kerwin, E. M.
Publicado 2020

Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease:...

por Driessen, M. T., Whalen, J., Seewoodharry Buguth, B., Vallejo-Aparicio, L. A., Naya, I. P., Asukai, Y., Alcázar-Navarrete, B., Miravitlles, M., García-Río, F., Risebrough, N. A.
Publicado 2018

Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulm...

por Driessen, M. T., Whalen, J., Buguth, B. Seewoodharry, Vallejo-Aparicio, L. A., Naya, I. P., Asukai, Y., Alcázar-Navarrete, B., Miravitlles, M., García-Río, F., Risebrough, N. A.
Publicado 2019